Peter Powchik, SVP Clinical Development & Reg at REGENERON PHARMACEUTICALS INC (REGN), sold 9,295 shares at $271.09 ($2.5M) on 2013-12-20, disclosed to the SEC on 2013-12-20.
Scheduled sale ($2.5M) by SVP Clinical Development & Reg under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $264.86 | 23 | $6K | 0.2% |
| 2 | $264.86 | 139 | $37K | 1.5% |
| 3 | $270.20 | 9,000 | $2.4M | 96.9% |
| 4 | $271.09 | 133 | $36K | 1.4% |
| Total | $270.12 avg | 9,295 | $2.5M | 100% |
| Filing → |
| REGN | SELL | 2014-01-03 | $5.7M | — | Filing → |
| REGN | SELL | 2013-12-17 | $2K | — | Filing → |
| REGN | SELL | 2013-01-04 | $2.5M | — | Filing → |